J Intensive Care:被动抬腿试验:无创监测可以指导脓毒症休克复苏吗?

2017-07-02 MedSci MedSci原创

及时足够的液体复苏是治疗脓毒症休克的基本策略。然而,复苏的先决条件是对液体容积反应性和液体复苏剂量进行评估。初期大量液体复苏及后期液体符合过重都可能会增加疾病死亡率。

及时足够的液体复苏是治疗脓毒症休克的基本策略。然而,复苏的先决条件是对液体容积反应性和液体复苏剂量进行评估。初期大量液体复苏及后期液体符合过重都可能会增加疾病死亡率。使用静态血压(例如中心静脉压或肺动脉压)对液体进行监测在某种程度上来说不够精确,因而不可取。动态的血流动力学监测(例如心搏量和动态血压)比起静态血压来说可以更好的预测液体的反应性,但是临床上患者的病情危重程度通常决定无条件进行动态的血流动力学监测。被动抬腿试验可以方便、快捷、无创、精确的在床旁对重症患者进行实时血流动力学和心排出量监测,从而可以对早期脓毒症休克患者进行液体复苏指导。总体来说,被动抬腿试验可以方便、快捷、无创、精确的在床旁对重症患者进行实时血流动力学和心排出量监测,从而可以对早期脓毒症休克患者进行液体复苏指导。原始出处:Honore PM1, Spapen HD1. Passive leg raising test with minimally invasive monitoring: the way forward for guiding septic shock resuscitation? J Inte

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038704, encodeId=8e932038e0407, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 14 21:56:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661209, encodeId=a131166120901, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Mon Mar 19 18:56:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305408, encodeId=d2461305408fb, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Tue Jul 04 02:56:00 CST 2017, time=2017-07-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038704, encodeId=8e932038e0407, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 14 21:56:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661209, encodeId=a131166120901, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Mon Mar 19 18:56:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305408, encodeId=d2461305408fb, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Tue Jul 04 02:56:00 CST 2017, time=2017-07-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038704, encodeId=8e932038e0407, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon May 14 21:56:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661209, encodeId=a131166120901, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Mon Mar 19 18:56:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305408, encodeId=d2461305408fb, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Tue Jul 04 02:56:00 CST 2017, time=2017-07-04, status=1, ipAttribution=)]
    2017-07-04 lizhou0204